期刊
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 142, 期 1, 页码 24-+出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2018.05.018
关键词
Eosinophilic esophagitis; gastroesophageal reflux disease; dysphagia; food allergy; esophageal strictures; esophagitis
资金
- National Institutes of Health Consortium of Eosinophilic Gastrointestinal disease Researchers (CEGIR), Rare Disease Clinical Research Network, an initiative of the Office of Rare Diseases Research, the National Center for Advancing Translational Sciences ( [U54 AI117804]
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases
- NCATS
- APFED CURED
- EFC
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [K08DK097721]
The scientific basis and the clinical application of mAb therapies that target specific immunologic pathways for eosinophilic gastrointestinal diseases are areas of active interest. There is a growing recognition of a subset of patients with eosinophilic esophagitis whose disease does not respond well to topical steroids or elimination diets. In addition, long-term use of corticosteroids presents possible risks that are currently being evaluated. Systemic therapy with a biologic agent offers potential advantages as a global approach that could limit the need for multiple, locally active medical therapies and allergen avoidance. The identification of novel biologic strategies is ongoing, and the recent validation of instruments and outcome measures to assess disease activity has proved essential in demonstrating efficacy. Studies using biologics that target IL-13 pathways in the treatment of eosinophilic esophagitis have demonstrated substantial promise.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据